It’s our favorite month – #ALSAwarenessMonth !

Join us this May as we support and honor families impacted by ALS, celebrate innovative breakthroughs, make the science more accessible, and share progress toward a world where everyone with ALS lives.

#ResearchMatters #endALS

The 2024 Target ALS Annual Meeting will be held next week in #Boston , gathering hundreds from the #ALSresearch community: bit.ly/3JMWmFT #EndALS

Thanks to our sponsors: Biogen Merck Prevail Therapeutics QurAlis Takeda Mitsubishi Tanabe Pharma America Eli Lilly and Company Regeneron Novartis

In collaboration with DNAstack and Verily, Target ALS has launched a first-of-its-kind data portal that will provide no-strings-attached access to comprehensive datasets and analysis tools to fuel the discovery of treatments and biomarkers for #ALS .
bit.ly/3IX97gJ

Renowned physician-scientist, Sarah Isabel Sheikh recently joined our Board of Directors, bringing instrumental expertise in collaborative models to advance research and vast knowledge of clinical neuroscience, drug discovery, and clinical trials.

#ALSResearch #EveryoneLives

🔬 New funding opportunity! 🔬

We are seeking collaborative groups to work on identifying novel biomarkers for disease stratification and progression in ALS. LOIs are due May 29, 2024.

Learn more and submit your LOI at bit.ly/4ctIZrj.

#ALSResearch #GrantOpportunity

How long does each stage of ALS last? ⏳

Most patients progress to the end stages of ALS within three to five years from diagnosis, and the disease is eventually terminal.

Read more ALS FAQs: targetals.org/faq/

#ALS #ALS Facts #ALS FAQ

Our Innovation Ecosystem unites academia’s deep understanding of disease biology with the pharmaceutical industry’s expertise in drug development.

This model has led to the initiation of seven #ALS ClinicalTrials with unprecedented speed over the last decade.

#ALS Research #ALS

#New in vivo target validation in-kind grant opportunity, in partnership with Biospective, Inc., allowing investigators to evaluate the effect of modulating a candidate therapeutic target on #ALS phenotypes in a TDP-43 mouse model. Learn more: bit.ly/3T5lEmY #alsresearch

Encouraging more investigators to work on ALS is central to our strategy to accelerate innovative research. Live Like Lou is accepting applications for their Postdoctoral Fellowship Program, encouraging emerging scientists to focus on ALS. Learn more at bit.ly/3IB8IAJ

#RareDiseasesDay | At Target ALS, our commitment spans all forms of #ALS , including the rarest forms. Through collaborative efforts with esteemed partners such as n-Lorem Foundation, we are advancing drug discovery for nano-rare ALS mutations.

#ALS Research

Rare Disease Day

How is ALS diagnosed?

#ALS is primarily diagnosed based on symptoms observed by a physician during physical examination, along with a review of the patient’s medical history and tests to rule out other diseases.

Read more ALS FAQs: targetals.org/faq/

#ALS Facts #ALS FAQ

Dr. Hemali Phatnani, PhD is working to answer elusive questions that can transform our understanding of ALS-FTD. 🧠

Her work (funded by TALS) will decode which specific genes are changing in healthy or sick neurons and neighboring cells within #ALS and #FTD cases.

Our Natural History study will expand to 18 international sites, addressing an ongoing barrier to investigating the evolution of #ALS over time in patients – the lack of ethnic, genetic, and geographic diversity among study participants.

Learn more 👉 bit.ly/42FHW3a

Celebrating #RareDiseaseAwarenessMonth 🎉

Target ALS is committed to finding treatment for all forms of #ALS , including the ultra-rare genetic forms of the disease, each of which affects a handful of individuals worldwide. 🌎

#UltraRareALS #ALS Research #EveryoneLives

Javier Oroz, PhD, aims to improve the efficiency of ALS diagnoses, which remains notoriously difficult to do.

His lab is working to identify the TDP-43 protein in patient samples to reliably diagnose #ALS , and run more effective clinical trials.

Breaking News! 🧪

Biofluid samples, including CSF, blood, & urine, from our ongoing Natural History Study are now available for global distribution to scientists advancing #ALS Research .

Learn more: bit.ly/42tE3OL

Request Samples: bit.ly/3SJhCSq

#ALS

What is the difference between familial ALS and sporadic ALS?

Familial ALS is caused by mutations passed down in families. Sporadic ALS is diagnosed in 90% of cases where there is no family history of ALS.

Read more ALS FAQs: targetals.org/faq/

#ALS #ALS Facts #ALS FAQ

In a recent episode of the #FutureForward Podcast, Dan shares his personal experiences with #ALS , how it has reshaped his perspective, and his relentless efforts in pioneering research and treatment options for this disease.

Listen now: bit.ly/47KmsmD

#EveryoneLives

Over the last 10 years, Target ALS has transformed the #ALS Research landscape through our landmark Innovation Ecosystem.

As we enter our second decade, we have launched our bold 7 Pillar Strategy to defeat #ALS . Watch to learn more about our approach.

#EveryoneLives #ALS

New York Governor Kathy Hochul recently proposed a groundbreaking proposal allocating $25M to propel ALS research and care forward.

It's a privilege to participate in this collaborative effort.
Read more in The New York Times: nyti.ms/3SqEoya

#EveryoneLives